# Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

> **NCT04880187** · PHASE2 · UNKNOWN · sponsor: **Axcella Health, Inc** · enrollment: 273 (estimated)

## Conditions studied

- Non Alcoholic Steatohepatitis (NASH)

## Interventions

- **DRUG:** AXA1125
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04880187
- **Lead sponsor:** Axcella Health, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-07
- **Primary completion:** 2023-09
- **Final completion:** 2023-10
- **Target enrollment:** 273 (ESTIMATED)
- **Last updated:** 2022-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04880187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04880187, "Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04880187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*